Further advances in HIV prevention, treatment and cure from PLOS Medicine's special issue

November 30, 2017, Public Library of Science

This week, guest editors Steven G. Deeks of the University of California San Francisco, USA; Sharon Lewin of the Peter Doherty Institute of Infection and Immunity, University of Melbourne and Royal Melbourne Hospital, Australia; and Linda-Gail Bekker of the Desmond Tutu HIV Centre, University of Cape Town, South Africa sum up PLOS Medicine's special issue on Advances in HIV Prevention, Treatment and Cure in an Editorial published to coincide with World AIDS Day on December 1. While it may appear that "the goal of ending the epidemic is in our grasp", they caution that "the remarkable progress, activism, resources, ingenuity and sheer fortitude that have brought us this far will be needed in at least equal measure to take us to the end."

In an accompanying Perspective, Chris Beyrer and colleagues discuss the growing HIV epidemic in the Russian Federation, where the available prevention measures have failed to stem an increase in HIV infections, particularly in people who inject drugs and men who have sex with men. The authors note that "The continuous growth of the Russian HIV epidemic is a failure of public policy and practice" and warn of the serious consequences of neglecting this epidemic. In a Research Article addressing issues of HIV prevention in India, Sunil Solomon and colleagues present a large study using respondent-driven sampling to identify people with HIV and hepatitis C virus infection in key populations. With global targets seeking to bring about swift progress in bringing the HIV epidemic under control, this method appears promising as a way to efficiently identify people with treatable virus infections.

Continuing the theme of early identification of infection so as to ensure prompt treatment initiation and limit further virus transmission, Katrina Ortblad and colleagues report in their Research Article on a cluster-randomized controlled trial of delivery models for HIV self-testing among female sex workers in Uganda. In one delivery model, peer educators directly provided the HIV self-test to ; in the other model, the peer educators gave the sex workers a coupon that could be exchanged for an HIV self-test at a healthcare facility. Participants in both HIV self-testing arms were significantly more likely to test and re-test for HIV, compared to the standard of care arm. The direct provision delivery model was more effective than passively offering the HIV self-tests for collection at healthcare facilities. The authors conclude that "self-testing can play an important role in supporting interventions that require frequent HIV testing."

In an epidemiological study, Jacob Bor and colleagues studied a large cohort of more than 11,000 people who entered HIV care in South Africa in 2011-2012, when eligibility for antiretroviral treatment was dependent on CD4 cell count. The authors found that patients eligible for immediate antiretroviral treatment had a significantly greater retention in care than those narrowly failing the eligibility criteria. These findings support the current WHO recommendations to provide antiretroviral therapy regardless of CD4 count, and the authors highlight that "the real-world benefits of extending ART eligibility to all patients ... may be larger than previously thought."

Though of great interest, curing HIV infection has been very rarely achieved, to date. In a further research paper, Andrew Badley and colleagues describe the case of a person with HIV who underwent an allogeneic stem cell transplant as treatment for acute lymphoblastic leukaemia, and report analyses of virus sequence and tissue distribution throughout the process. Although the patient's HIV reservoir was diminished by treatment, viral rebound was observed to have occurred after a prolonged period (288 days) without antiretroviral therapy. These findings should be valuable in guiding further attempts to cure HIV infection using stem cell transplantation and other methods.

Explore further: Advances in HIV Prevention, Treatment and Cure: a special issue of PLOS Medicine

More information: Deeks SG, Lewin SR, Bekker L-G (2017) The end of HIV: Still a very long way to go, but progress continues. PLoS Med 14(11): e1002466. doi.org/10.1371/journal.pmed.1002466

Related Stories

Advances in HIV Prevention, Treatment and Cure: a special issue of PLOS Medicine

November 7, 2017
This week, publication of a special issue on Advances in HIV Prevention, Treatment and Cure begins in PLOS Medicine, advised by guest editors Linda-Gail Bekker of the Desmond Tutu HIV Centre, University of Cape Town, South ...

Immediate ART treatment improves retention rates

November 28, 2017
Starting antiretroviral therapy (ART) immediately following an HIV diagnosis dramatically improves retention in clinical HIV care, according to a study led by a Boston University School of Public Health (BUSPH) researcher.

Only one-third of HIV-positive patients remain in care before starting treatment

July 19, 2011
In sub-Saharan Africa, only about one third of patients who test positive for HIV but are not yet eligible for antiretroviral treatment remain in care until they become eligible and start treatment. Some patients never return ...

Controlling the HIV epidemic: A progress report on efforts in sub-Saharan Africa

May 2, 2017
In a Research Article published in PLOS Medicine, Richard Hayes of the London School of Hygiene & Tropical Medicine, UK and colleagues report early findings from PopART—a clinical trial evaluating an intervention to achieve ...

Improved retention and outcomes with same-day HIV testing and treatment

July 25, 2017
Initiating antiretroviral therapy (ART) on the same day as HIV testing is feasible and leads to improved retention and health outcomes, according to a trial published in PLOS Medicine.

Girl's HIV infection seems under control without AIDS drugs

July 24, 2017
A South African girl born with the AIDS virus has kept her infection suppressed for more than eight years after stopping anti-HIV medicines—more evidence that early treatment can occasionally cause a long remission that, ...

Recommended for you

Researchers find new way to defeat HIV latency

March 8, 2018
HIV, the virus that causes AIDS, has a secret life. Though anti-retroviral therapy can reduce its numbers, the virus can hide and avoid both treatments and the body's immune response.

Broadly neutralizing antibody treatment may target viral reservoir in monkeys

March 5, 2018
After receiving a course of antiretroviral therapy for their HIV-like infection, approximately half of a group of monkeys infused with a broadly neutralizing antibody to HIV combined with an immune stimulatory compound suppressed ...

HIV begins to yield secrets of how it hides in cells

March 2, 2018
UC San Francisco scientists have uncovered new mechanisms by which HIV hides in infected cells, resting in a latent state that evades the body's immune system and prevents antiviral drugs from flushing it out.

HIV exports viral protein in cellular packages

February 15, 2018
HIV may be able to affect cells it can't directly infect by packaging a key protein within the host's cellular mail and sending it out into the body, according to a new study out of a University of North Carolina Lineberger ...

Can gene therapy be harnessed to fight the AIDS virus?

February 13, 2018
For more than a decade, the strongest AIDS drugs could not fully control Matt Chappell's HIV infection. Now his body controls it by itself, and researchers are trying to perfect the gene editing that made this possible.

Big data methods applied to the fitness landscape of the HIV envelope protein

February 7, 2018
Despite significant advances in medicine, there is still no effective vaccine for the human immunodeficiency virus (HIV), although recent hope has emerged through the discovery of antibodies capable of neutralizing diverse ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.